Glenmark Pharma, USA acquires approved ANDAs from Wockhardt
28 June 2022 | News
Expands its OTC portfolio
Image Credit: Shutterstock
Glenmark Pharmaceuticals announced that its fully owned subsidiary Glenmark Pharmaceuticals Inc, USA (Glenmark) has acquired the approved Abbreviated New Drug Applications (ANDAs) for Famotidine Tablets USP, 10 mg and 20 mg (OTC), Cetirizine Hydrochloride Tablets USP, 5 mg and 10 mg (OTC), Lansoprazole Delayed-Release Capsules USP, 15 mg (OTC) and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 per cent (OTC) in the US from Wockhardt.
Sanjeev Krishan, President of Glenmark Pharmaceuticals, USA, said, "Our acquisition of these ANDAs
represents the continued expansion of our business into the OTC market here in the US and our commitment to ensuring patients have access to high quality, affordable medicines.”
